A Study of BBI503 in Adult Patients With Advanced Gastrointestinal Stromal Tumors
Status:
Terminated
Trial end date:
2017-07-25
Target enrollment:
Participant gender:
Summary
This is an open label, multi-center, phase II study of BBI503 administered to adult patients
with advanced gastrointestinal stromal tumor who have exhausted all currently approved
standard anti-cancer treatment options. BBI503 will be administered orally, daily, in
continuous 28-day cycles at a dose of 300 mg once daily. Cycles will be repeated until
patients are no longer clinically benefiting from therapy due to disease progression, adverse
events, or another discontinuation criterion.
Safety, tolerability and efficacy of BBI503 will be assessed for the duration of study
treatment.
Phase:
Phase 2
Details
Lead Sponsor:
Boston Biomedical, Inc Sumitomo Dainippon Pharma Oncology, Inc